Business
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical
About this update from Galmed Pharmaceuticals Ltd.
[{"type":"text","content":"TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the United States Patent and Trademark Office (USPTO) granted Galmed new patents related to the use of Aramchol for the treatment of fibrosis and for the treatment for modulating gut microbiota. An additional patent grant protects the low dose composition of Aramchol salt until June 8, 2036. With these latest patents, Galmed is strengthening and extending the IP protection of its lead compound, Aramchol, until December 2038.\nThe three new patents relate to:\nThe grant of a US patent (US 11,197,870 B2, expiring October 20, 2037) claims the use of Aramchol or salts thereof (e.g. Aramchol Meglumine) for the treatment of hepatic fibrosis. The patent supports the direct anti fibrotic effect of Aramchol in liver, where the hepatic fibrosis is not associated with NAFLD or NASH. The grant of a US patent (US 11,166,964 B2), directed to the use of Aramchol or salts thereof (e.g. Aramchol Meglumine) for the treatment of dysbiosis of the gastrointestinal (GI) tract opens potential new treatment modalities for Aramchol in GI pathology and extends Galmed's proprietary Aramchol Meglumine patent protection until December 1, 2038. The grant of a US patent (US 10,849,911 B2) for low dose composition of Aramchol salt extends Aramchol intellectual property protection until June 8, 2036, claiming a salt of Aramchol, including the Meglumine Salt, as a composition of matter and for the treatment of NAFLD and NASH.\"The past 12 months have been an exciting time for Galmed as we reported positive, interim data from the Open Label part of our Phase 3 ARMOR clinical trial for the treatment of NASH and fibrosis. As such, we are delighted that these newly granted patents help secure broad IP rights underpinning Aramchol and its salts. We believe the granting of these patents provides us the necessary protection to expand our clinical development program,\" noted Allen Baharaff, President and CEO of Galmed.\nGalmed Pharmaceuticals Ltd.\nGalmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Their lead compound, Aramchol™, a backbone drug can...